Max Healthcare Institute Limited has announced the initiation of voluntary liquidation proceedings for its wholly-owned subsidiary MHC Global Healthcare (Nigeria) Limited under the applicable laws of Nigeria. The company disclosed this development on January 29, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Impact Assessment

The subsidiary's contribution to the group's consolidated financials as of March 31, 2025, demonstrates minimal impact on the parent company's overall performance:

The negative networth of ₹70,89,724 represents a negligible percentage of the consolidated financials, reinforcing the subsidiary's non-material status.

Corporate Structure and Business Impact

Max Healthcare Institute Limited has emphasized that MHC Global Healthcare (Nigeria) Limited is not classified as a material subsidiary of the company. The management has assured stakeholders that the voluntary liquidation process will neither affect any existing business operations nor create a material impact on the company's consolidated financial statements.

Liquidation Process and Timeline

MHC Nigeria has initiated the process for filing the requisite application with the Corporate Affairs Commission and other relevant authorities in Nigeria for voluntary liquidation. The company has committed to providing further updates to the stock exchanges upon completion of the liquidation formalities.

Regulatory Compliance

The disclosure was made in accordance with SEBI regulations, with the company receiving the intimation on January 29, 2026, at 5:23 PM IST. The announcement has been communicated to both the National Stock Exchange of India Limited and BSE Limited, and the disclosure is also hosted on the company's official website at www.maxhealthcare.in .

This strategic decision reflects Max Healthcare's focus on optimizing its corporate structure by divesting non-performing international subsidiaries while maintaining its core healthcare operations in India.

Max healthcare institute has officially notified stock exchanges about its upcoming board meeting scheduled for February 5, 2026, where directors will review and approve the company's quarterly financial performance. The meeting represents a key milestone in the company's financial reporting calendar as stakeholders await insights into the healthcare provider's operational and financial performance.

Board Meeting Details

The company has formally communicated to both the National Stock Exchange of India Limited and BSE Limited regarding the board meeting scheduled for Thursday, February 5, 2026. The primary agenda involves consideration and approval of unaudited standalone and consolidated financial results covering two distinct periods.

Regulatory Compliance and Trading Window

In accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Max Healthcare Institute has maintained transparency by providing advance notice of the board meeting. The company has implemented trading restrictions as part of its compliance framework.

The trading window closure affects specific categories of individuals and extends beyond the meeting date to ensure fair disclosure practices. This restriction continues from the earlier intimation dated December 29, 2025, demonstrating the company's adherence to regulatory timelines.

Communication and Disclosure

The company has ensured comprehensive communication by notifying both major stock exchanges where its securities are listed. Max Healthcare Institute trades on NSE under the symbol MAXHEALTH and on BSE with scrip code 543220. The formal communication was signed by Dhiraj Aroraa, SVP - Company Secretary and Compliance Officer, on January 28, 2026.

Additionally, the company has committed to hosting this disclosure on its official website at www.maxhealthcare.in , ensuring broader accessibility for stakeholders and maintaining transparency in its communication approach. This multi-channel disclosure strategy aligns with best practices in corporate governance and regulatory compliance.